<DOC>
	<DOCNO>NCT01485302</DOCNO>
	<brief_summary>Primary Objective : - To assess safety tolerability escalate single multiple dos SAR228810 patient Alzheimer 's disease ( AD ) Secondary Objective : - To evaluate pharmacokinetic property SAR228810 escalate single multiple dos SAR228810 AD patient</brief_summary>
	<brief_title>Single Repeated Dosing Study Assess Safety Concentration-time Profile SAR228810 Alzheimer 's Patients</brief_title>
	<detailed_description>14.5 22 month</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Male female patient mild moderate Alzheimer 's disease , age 50 85 year inclusive Meets criteria probable Alzheimer 's National Institute Neurologic Communicative Disorders Stroke Alzheimer 's Disease Related Disorders Association Minimental state examination ( MMSE ) In reasonable stable health state Alzheimer 's patient age stage disease assess comprehensive clinical assessment Magnetic resonance image consistent Alzheimer 's disease , indicate cause dementia symptom Alzheimer 's disease Rosen Modified Hachinski Ischemic score If symptomatic treatment Alzheimer 's disease ( acetylcholinesterase inhibitor or/and memantine ) , must stable last 30 day screen Exclusion criterion : Clinically significant neurological disease Alzheimer 's disease Had major psychiatric disorder Had history stroke , seizure , brain neoplasm , brain surgery , cerebrovascular disorder ( include transient ischemic attack ) History presence severe , uncontrolled and/or unstable angiopathy vasculitis . History presence clinically relevant cardiac disease . Currently take anticonvulsant , antiParkinsonians , antipsychotic , anticoagulant narcotic drug , recent immunosuppressive cancer chemotherapy drug , cognitive enhancer . Concomitant therapy allow give stable dose least 30 day screen : acetylcholinesterase inhibitor and/or memantine ; antidepressant class selective serotonin reuptake inhibitor ( tricyclic ) ; acetyl salicylic acid ( ASA ) dose â‰¤ 160 mg/day ; The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>mild moderate Alzheimer 's Disease</keyword>
</DOC>